# Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

> **NCT03273257** · PHASE2 · TERMINATED · sponsor: **International CTEPH Association** · enrollment: 14 (actual)

## Conditions studied

- Chronic Thromboembolic Pulmonary Hypertension
- CTEPH

## Interventions

- **DRUG:** Riociguat
- **DRUG:** Placebo
- **PROCEDURE:** Pulmonary endarterectomy

## Key facts

- **NCT ID:** NCT03273257
- **Lead sponsor:** International CTEPH Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-17
- **Primary completion:** 2020-05-05
- **Final completion:** 2020-05-05
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The study was stopped due to slower than expected recruitment and the additional limitations on clinical research imposed by the COVID-19 pandemic, both of which made study completion within a reasonable timeframe appear unlikely.
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03273257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03273257, "Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03273257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*